Viatris Earnings Preview: What to Expect

Company Overview - Viatris Inc. (VTRS) is a global pharmaceutical and healthcare company with a market cap of $14.6 billion, formed in November 2020 and headquartered in Canonsburg, Pennsylvania. The company develops, manufactures, and distributes a wide range of generic, branded, complex generic, and biosimilar medicines across more than 165 countries, serving approximately 1 billion patients annually [1]. Earnings Expectations - Analysts anticipate that VTRS will report a profit of $0.53 per share on a diluted basis for fiscal 2025 fourth-quarter earnings, reflecting a decrease of 1.9% from $0.54 per share in the same quarter last year. The company has exceeded consensus estimates in three of the last four quarters while missing on one occasion [2]. - For the full fiscal year 2025, analysts expect VTRS to report earnings per share (EPS) of $2.33, which is a decline of 12.1% from $2.65 in fiscal 2024. However, EPS is projected to increase by 6.4% year over year to $2.48 in fiscal 2026 [3]. Stock Performance - VTRS stock has increased by 15.2% over the past year, outperforming the S&P 500 Index's gain of 13.7% and the Health Care Select Sector SPDR Fund's increase of 11.1% during the same period [4]. Product Launch - On January 20, Viatris launched its heart failure treatment, Inpefa (sotagliflozin), in the United Arab Emirates, marking its first commercial launch in international markets. Inpefa is the first dual SGLT1/2 inhibitor approved for heart failure, aimed at reducing the risk of cardiovascular death and related hospitalizations, thereby enhancing Viatris' cardiovascular portfolio and innovative pipeline. Following the announcement, VTRS shares rose by 3.1% in the subsequent trading session [5]. Analyst Ratings - The consensus opinion on VTRS stock is cautious, with an overall "Moderate Buy" rating. Among ten analysts covering the stock, four recommend a "Strong Buy," five suggest a "Hold," and one advises a "Moderate Sell." VTRS is currently trading above its average analyst price target of $13 [6].